Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence ; volume:20 ; number:1 ; day:18 ; month:8 ; year:2021 ; pages:1-12 ; date:12.2021
Cardiovascular diabetology ; 20, Heft 1 (18.8.2021), 1-12, 12.2021
- Urheber
-
Schechter, Meir
Melzer-Cohen, Cheli
Rozenberg, Aliza
Yanuv, Ilan
Chodick, Gabriel
Karasik, Avraham
Kosiborod, Mikhail
Mosenzon, Ofri
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-021-01362-y
- URN
-
urn:nbn:de:101:1-2021110608361614741116
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:30 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Schechter, Meir
- Melzer-Cohen, Cheli
- Rozenberg, Aliza
- Yanuv, Ilan
- Chodick, Gabriel
- Karasik, Avraham
- Kosiborod, Mikhail
- Mosenzon, Ofri
- SpringerLink (Online service)
Ähnliche Objekte (12)
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease
Hepatic benefits of sodium-glucose cotransporter 2 inhibitors in liver disorders
Prevention of Cardiorenal Complications with Sodium–Glucose Cotransporter Type 2 Inhibitors: A Narrative Review
Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium–Glucose Cotransporter 2 Inhibitors
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
Sodium-Glucose Co-Transporter 2 Inhibitors and Fracture Risk
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter 2 (SGLT2) Inhibition in Kidney Transplant Recipients with Diabetes Mellitus
Sodium-Glucose Cotransporter-2 Inhibition and the Glomerulus: A Review
Sodium‑glucose co-transporter‑2 inhibitors in the treatment of diabetes with heart failure
Hepatic expression of sodium–glucose cotransporter 2 (SGLT2) in patients with chronic liver disease